FrancophonIA/ELRC3.0 huggingface dataset:
English: In particular, tell your doctor if you are using medicines containing any of the following active substances: - ketoconazole, used to treat fungal infections ritonavir, used to treat HIV infection - rifampicin, an antibiotic used to treat bacterial infections - carbamazepine, phenytoin or phenobarbital used to treat epilepsy - St. John's Wort (Hypericum perforatum), used for depression or other conditions - oral antidiabetics
Croatian: Posebno naglasite svome liječniku ako koristite lijek koji u svom sastavu ima sljedeće tvari: - ketokonazol, za liječenje gljivičnih infekcija - ritonavir, uzima se za liječenje HIV infekcije - rifampicin, antibiotik za liječenje bakterijskih infekcija - karbamazepin, fenitoin ili fenobarbital za liječenje epilepsije - Gospinu travu (Hypericum perforatum) koja se primjenjuje kod depresije ili drugih stanja - oralne antidijabetike.
English: Include all radiological CR+CRu+PR by IRC regardless the verification by bone marrow and LDH.
Croatian: Uključuje sve radiološke CR+CRu+PR prema IRC neovisno o potvrdi koštanom srži i LDH.
English: • Increased or decreased urine production (due to kidney damage), painful passing of urine or blood/proteins in the urine, fluid retention
Croatian: • pojačana ili smanjena proizvodnja mokraće (zbog oštećenja bubrega), bolno mokrenje ili krv/bjelančevine u mokraći, zadržavanje tekućine
English: Mood disorders and disturbances*, Anxiety disorder*, Sleep disorders and disturbances*
Croatian: Poremećaji i smetnje raspoloženja *, anksiozni poremećaj*, poremećaji i smetnje spavanja*
English: • fainting, dizziness or light-headedness in the past
Croatian: • nesvjesticu, omaglicu ili ošamućenost u prošlosti
English: The incidence of all grade peripheral neuropathy with VELCADE administered intravenously was lower in the historical studies with VELCADE administered intravenously than in study MMY-3021.
Croatian: Incidencija periferene neuropatije svih stupnjeva uz intravensku primjenu lijeka VELCADE bila je niža u prethodnim ispitivanjima s lijekom VELCADE primijenjenim intravenski, nego u ispitivanju MMY-3021.
English: This medicine is for intravenous or subcutaneous use.
Croatian: Ovaj lijek je namijenjen za primjenu intravenski ili supkutano.
English: Therefore, caution should be used during handling and preparation of VELCADE.
Croatian: Stoga je potreban oprez tijekom rukovanja i pripreme lijeka VELCADE.
English: You will have to take regular blood tests before and during your treatment with VELCADE, to check your blood cell counts regularly.
Croatian: Imati ćete redovne kontrole krvi prije i tijekom liječenja lijekom VELCADE, kako bi se redovito provjerio broj krvnih stanica.
English: The median TTP was 6.5 months for the VELCADE monotherapy patients compared with 9.3 months for the VELCADE plus pegylated liposomal doxorubicin combination therapy patients.
Croatian: Medijan TTP-a bio je 6,5 mjeseci za bolesnike na monoterapiji lijekom VELCADE u usporedbi s 9,3 mjeseci za bolesnike na kombiniranoj terapiji lijekom VELCADE plus pegilirani liposomalni doksorubicin.
English: Posterior Reversible Encephalopathy Syndrome (PRES) There have been reports of PRES in patients receiving VELCADE.
Croatian: Bili su prijavljeni slučajevi sindroma posteriorne reverzibilne encefalopatije (PRES) kod bolesnika koji su primali VELCADE.
English: Discontinuation due to PN (%)
Croatian: Prekid radi PN (%)
English: Include all CR+CRu, by IRC, bone marrow and LDH.
Croatian: Uključuje sve CR + CRu, prema IRC, koštanu srž i LDH.
English: • Alteration of liver function
Croatian: • promijenjena funkcija jetre
English: A pharmacokinetic study was conducted in patients with various degrees of renal impairment who were classified according to their creatinine clearance values (CrCL) into the following groups: Normal (CrCL ≥ 60 ml/min/1.73 m2, n=12), Mild (CrCL=40-59 ml/min/1.73 m2, n=10), Moderate
Croatian: Provedeno je farmakokinetičko ispitivanje u bolesnika s različitim stupnjevima oštećenja bubrega koji su bili podijeljeni prema vrijednostima klirensa kreatinina (CrCL) u sljedeće skupine: normalno (CrCL ≥ 60 ml/min/1,73 m2, n = 12), blago (CrCL = 40-59 ml/min/1,73 m2, n = 10), umjereno
English: As this medicine is being given by your doctor or nurse, it is unlikely that you will be given too much.
Croatian: Ako primijenite više lijeka VELCADE nego što ste trebali Budući da Vam ovaj lijek daje liječnik ili medicinska sestra, nije vjerojatno da će Vam se primijeniti previše lijeka.
English: In the Phase III study, treatment with VELCADE led to a significantly longer time to progression, a significantly prolonged survival and a significantly higher response rate, compared to treatment with dexamethasone (see Table 14), in all patients as well as in patients who have received 1 prior line of therapy.
Croatian: U ispitivanju faze III, liječenje lijekom VELCADE značajno je produljilo vrijeme do progresije bolesti i dovelo do značajno produljenog preživljenja te značajno veće stope odgovora u usporedbi s liječenjem deksametazonom (vidjeti tablicu 14) u svih bolesnika, kao i u bolesnika koji su prethodno primili 1 liniju terapije.
English: In a study in previously untreated mantle cell lymphoma patients, 42.9% and 10.4% of patients exposed to VELCADE were in the range 65-74 years and ≥ 75 years of age, respectively.
Croatian: U ispitivanju kod bolesnika s prethodno neliječenim limfomom plaštenih stanica, 42,9% i 10,4% bolesnika izloženih lijeku VELCADE bilo je dobi unutar raspona 65-74 godine odnosno ≥ 75 godina starosti.
English: The reconstituted solution should be used immediately after preparation.
Croatian: Rekonstituirana otopina se mora primijeniti odmah nakon pripreme.
English: Patients with baseline Grade ≥ 2 peripheral neuropathy or platelet counts < 50,000/µl were excluded.
Croatian: Bolesnici s osnovnom perifernom neuropatijom stupnja ≥ 2 ili s brojem trombocita < 50 000/µl bili su isključeni.
English: Intent to Treat (ITT) population p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p < 0.0001
Croatian: p-vrijednost iz stratificiranog log-rank testa; analiza po liniji liječenja isključuje stratifikaciju po prethodnim liječenjima; p < 0,0001
English: Following a review of post-marketing cases and literature reports for the period covered by this PSUR, 158 cases of “Lid, lash and lacrimal infections, irritations and inflammations” were retrieved in patients who received bortezomib.
Croatian: Nakon pregleda slučajeva po stavljanju lijeka u promet i slučajeva prijavljenih u literaturi u razdoblju koje pokriva ovaj PSUR, za bolesnike koji su primali bortezomib pronađeno je 158 slučajeva “Infekcije, iritacije i upale kapaka, trepavica i lakrimalnog sustava”.
English: > 3 x ULN
Croatian: > 3x GGN
English: Intent to Treat Population n=74
Croatian: Populacija uključena u ispitivanje n = 74
English: When VELCADE is given in combination with thalidomide you must follow the pregnancy prevention programme for thalidomide (see package leaflet for thalidomide).
Croatian: Kada se VELCADE daje zajedno s talidomidom, morate slijediti program namijenjen prevenciji trudnoće za talidomid (vidjeti uputu o lijeku za talidomid).
English: In a clinical trial, two patients (out of 2) given high-dose cytarabine (2 g/m2 per day) by continuous infusion over 24 hours with daunorubicin and VELCADE for relapsed acute myelogenous leukaemia died of ARDS early in the course of therapy, and the study was terminated.
Croatian: Tijekom kliničkog ispitivanja, dvoje bolesnika (od 2) koji su primali visoku dozu citarabina (2 g/m 2 na dan) kontinuiranom infuzijom u trajanju od 24 sata s daunorubicinom i lijekom VELCADE zbog relapsa akutne mijeloične leukemije umrla su od ARDS na početku liječenja, a ispitivanje je bilo prekinuto.
English: • Paralysis, seizures, falling, movement disorders, abnormal or change in, or reduced sensation
Croatian: • paraliza, napadaji, padovi, poremećaji pokreta, abnormalnost ili promjena u, ili smanjen osjet
English: Patients with pre-existing severe neuropathy may be treated with VELCADE only after careful risk/benefit assessment.
Croatian: Bolesnici s već prisutnom teškom neuropatijom mogu se liječiti lijekom VELCADE nakon pomne procjene omjera rizika i koristi.
English: Melphalan (9 mg/m2) and prednisone (60 mg/m2) are both given orally on days 1, 2, 3 and 4 of the first week of each cycle.
Croatian: Melfalan (9 mg/m2) i prednizon (60 mg/m2) primjenjuju se na usta i daju se 1., 2., 3. i 4. dana prvog tjedna primjene tijekom svih ciklusa.
English: • Injection site or injection device related disorders
Croatian: • poremećaji na mjestu primjene injekcije ili poremećaj povezan s uređajem kojim se daje injekcija
English: Instructions for reconstitution VELCADE must be reconstituted by a healthcare professional.
Croatian: Upute za pripremu VELCADE mora rekonstituirati zdravstveni radnik.
English: You will receive 4 cycles (12 weeks).
Croatian: Primit ćete 4 ciklusa (12 tjedana).
English: • Yellow discoloration of the eyes and skin (jaundice)
Croatian: • žućkasta boja očiju i kože (žutica)
English: Confirm concentration on vial to ensure that the correct dose is being given for the intravenous route of administration (1 mg/ml).
Croatian: Potvrdite koncentraciju na bočici kako biste osigurali da se primjenjuje ispravna doza za intravenski put primjene (1 mg/ml).
English: - The other ingredients are mannitol (E421) and nitrogen.
Croatian: - Pomoćne tvari su manitol (E421) i dušik.
English: VELCADE will be administered by a health care professional experienced in the use of cytotoxic medicines.
Croatian: VELCADE će Vam primijeniti zdravstveni radnik koji ima iskustvo u primjeni citotoksičnih lijekova.
English: The median age of the patients in the study was 71 years, 50% were male, 88% were Caucasian and the median Karnofsky performance status score for the patients was 80.
Croatian: Medijan dobi bolesnika u ispitivanju bio je 71 godina, 50% bili su muškarci, 88% bili su bijele rase a medijan rezultata funkcionalnog stanja po Karnofskom za bolesnike je bio 80.
English: Twice weekly VELCADE (cycles 1-4)
Croatian: VELCADE dva puta tjedno (1.-4. ciklus)
English: Transfusion reaction, Fractures*, Rigors*, Face injury, Joint injury*, Burns, Laceration, Procedural pain, Radiation injuries*
Croatian: Reakcije transfuzije, lomovi*, tresavica*, ozljeda lica, ozljeda zgloba*, opekline, laceracija, proceduralna bol, radijacijske ozljede*
English: • shingles (localised including around the eyes or spread across the body)
Croatian: • herpes zoster (lokalizirano, uključujući područje oko očiju ili prošireno po cijelom tijelu)
English: Based on Log rank test stratified with IPI risk and stage of disease.
Croatian: Temeljeno na Log rank testu stratificiranom s IPI rizikom i stadijem bolesti.
English: Uncommon Hepatitis B, Infection*, Bronchopneumonia
Croatian: Manje često Hepatitis B, infekcija*, bronhopneumonija
English: Gastrointestinal toxicity, including nausea, diarrhoea, vomiting and constipation are very common with VELCADE treatment.
Croatian: Gastrointestinalna toksičnost, uključujući mučninu, proljev, povraćanje i zatvor, vrlo su česti kod liječenja lijekom VELCADE.
English: • Decreased sex drive
Croatian: • smanjena spolna želja
English: • Low blood pressure, sudden fall of blood pressure on standing which may lead to fainting
Croatian: • nizak krvni tlak, nagli pad krvnog tlaka pri ustajanju, što može dovesti do nesvjestice
English: VELCADE must be reconstituted by a healthcare professional.
Croatian: VELCADE mora rekonstituirati zdravstveni radnik.
English: • bleeding problems and/or low number of platelets in your blood
Croatian: • tegobe s krvarenjem i/ili snižen broj krvnih pločica
English: • Blood clots in your lungs
Croatian: • krvni ugrušci u plućima
English: Six VELCADE cycles are recommended, although for patients with a response first documented at cycle 6, two additional VELCADE cycles may be given.
Croatian: Preporučuje se šest ciklusa liječenja lijekom VELCADE, iako se bolesnicima za koje je odgovor prvi put zabilježen u 6. ciklusu, mogu dati dva dodatna ciklusa liječenja lijekom VELCADE.
English: Aseptic technique must be strictly observed throughout the handling of VELCADE, since it contains no preservative.
Croatian: Aseptična tehnika mora se strogo poštovati tijekom cijelog postupka rukovanja lijekom VELCADE, budući da lijek ne sadrži konzervanse.
English: VELCADE intravenous arm
Croatian: VELCADE intravenska skupina
English: Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and stage of disease as stratification factors.
Croatian: Koristi se Mantel-Haenszelova procjena zajedničkog omjera izgleda za stratificirane tablice, s IPI rizikom i stadijem bolesti kao stratifikacijskim faktorima.
English: Patients in the VcTDx and TDx groups respectively had a median age of 57 versus 56 years, 99% versus 98% patients were Caucasians, and 58% versus 54% were males.
Croatian: Medijan dobi bolesnika u VcTDx odnosno TDx skupini, bio je 57 naspram 56 godina, 99% naspram 98% bolesnika bili su bijele rase, a 58% naspram 54% bili su muškarci.
English: A total of 74 evaluable patients were administered dexamethasone in combination with VELCADE.
Croatian: Ukupno je 74 bolesnika, koje se moglo procijeniti, primilo deksametazon u kombinaciji s lijekom VELCADE.
English: Dexamethasone was administered in combination with VELCADE to 83 patients in Cycle 1 with an additional 11 patients receiving dexamethasone during the course of VELCADE retreatment cycles.
Croatian: Deksametazon je bio primijenjen u kombinaciji s lijekom VELCADE u 83 bolesnika u 1. ciklusu, te u dodatnih 11 bolesnika koji su deksametazon primili tijekom ponovnog liječenja lijekom VELCADE.
English: • a dose-calculation tool that enables prescribers to input a patient's height and weight in order to calculate the body surface area (BSA) and thereby to determine the appropriate VELCADE dose.
Croatian: • instrument za izračun doze koji omogućava propisivaču lijeka da na osnovu unosa podataka o visini i težni bolesnika izračuna tjelesnu površinu (engl. body surface area, BSA), te tako odredi potrebnu dozu lijeka VELCADE.
English: Table 15: Summary of efficacy analyses comparing subcutaneous and intravenous administrations of VELCADE
Croatian: Tablica 15: Sažetak analize djelotvornosti usporedbe supkutane i intravenske primjene lijeka VELCADE
English: Retreatment of patients with relapsed multiple myeloma In a study in which VELCADE retreatment was administered in 130 patients with relapsed multiple myeloma, who previously had at least partial response on a VELCADE-containing regimen, the most common all-grade adverse events occurring in at least 25% of patients were thrombocytopenia (55%), neuropathy (40%), anaemia (37%), diarrhoea (35%), and constipation (28%).
Croatian: U ispitivanju u kojem se liječenje lijekom VELCADE primijenilo ponovno kod 130 bolesnika s relapsom multiplog mijeloma, koji su prethodno imali barem parcijalni odgovor na režim liječenja koji je uključivao VELCADE, najčešći štetni događaji svih stupnjeva, koji su se pojavili u barem 25% bolesnika bili su trombocitopenija (55%), neuropatija (40%), anemija (37%), proljev (35%) i konstipacija (28%).
English: • moderate to severe liver problems
Croatian: • umjereni do teški problemi s jetrom
English: The MAH shall ensure thatall healthcare professionals involved in the prescribing, dispensing, handling or administration of VELCADE are provided with educational material.
Croatian: Nositelj odobrenja će osigurati dostupnost edukacijskog materijala svim zdravstvenim radnicima koji su uključeni u postupak propisivanja, doziranje, pripremu i primjenu lijeka VELCADE.
English: • heart or blood pressure problems
Croatian: • tegobe sa srcem ili krvnim tlakom
English: CR=Complete Response; CRu=Complete Response unconfirmed; PR=Partial Response; CI=Confidence Interval, HR=Hazard Ratio; OR=Odds Ratio; ITT=Intent to Treat
Croatian: CR = Kompletni odgovor; CRu = Nepotvrđeni kompletni odgovor; PR = Djelomični odgovor; CI = Interval pouzdanosti, HR = Omjer hazarda; OR = Omjer izgleda; ITT = Populacija namijenjena za liječenje
English: The duration of overall response was 21.4 months longer in the VcR-CAP group (median 36.5 months versus 15.1 months in the R-CHOP group).
Croatian: Trajanje ukupnog odgovora bilo je 21,4 mjeseca duže u VcR-CAP skupini (medijan 36,5 mjeseci naspram 15,1 mjeseci u R-CHOP skupini).
English: Note: VELCADE is a cytotoxic agent.
Croatian: Važno: VELCADE je citotoksično sredstvo.
English: Limited information on VELCADE retreatment in relapsed multiple myeloma is available.
Croatian: Dostupni su ograničeni podaci o ponovljenom liječenju lijekom VELCADE pri relapsu mulitiplog mijeloma.
English: Bortezomib exposure is increased in patients with moderate or severe hepatic impairment; these patients should be treated with VELCADE at reduced doses and closely monitored for toxicities (see sections 4.2 and 5.2).
Croatian: Izloženost bortezomibu povećana je u bolesnika s umjereno ili teško oštećenom jetrom; te bolesnike treba liječiti smanjenim dozama lijeka VELCADE i pomno ih pratiti na znakove toksičnosti (vidjeti dijelove 4.2 i 5.2).
English: In patients with advanced myeloma the severity of thrombocytopenia was related to pre-treatment platelet count: for baseline platelet counts < 75,000/l, 90% of 21 patients had a count ≤ 25,000/l during the study, including 14% < 10,000/l; in contrast, with a baseline platelet count > 75,000/l, only 14% of 309 patients had a count ≤ 25,000/l during the study.
Croatian: U bolesnika s uznapredovalim mijelomom, težina trombocitopenije bila je povezana s brojem trombocita prije liječenja: kod početnog broja trombocita < 75 000/l, 90% od 21 bolesnika imalo je ≤ 25 000/l trombocita za vrijeme ispitivanja, uključujući njih 14% s < 10 000/l; nasuprot tome, kod početnog broja trombocita > 75 000/l, samo 14% od 309 bolesnika imalo je ≤ 25 000/l trombocita za vrijeme ispitivanja.
English: The median OS was 30.8 months (95% CI; 25.2-36.5 months) for the VELCADE monotherapy patients and 33.0 months (95% CI; 28.9-37.1 months) for the VELCADE plus pegylated liposomal doxorubicin combination therapy patients.
Croatian: Medijan OS bio je 30,8 mjeseci (95% CI; 25,2-36,5 mjeseci) za bolesnike na monoterapiji lijekom VELCADE i 33,0 mjeseci (95% CI; 28,9-37,1 mjeseci) za bolesnike na kombiniranom liječenju lijekom VELCADE s pegiliranim liposomalnim doksorubicinom.
English: Melphalan and prednisone should both be given orally on days 1, 2, 3 and 4 of the first week of each VELCADE treatment cycle.
Croatian: Melfalan i prednizon trebaju se primijeniti oralno 1., 2., 3. i 4. dan prvog tjedna svakog ciklusa liječenja lijekom VELCADE.
English: OR for response rates based on Mantel-Haenszel estimate of the common odds ratio for stratified tables; p-values by Cochran Mantel-Haenszel test.
Croatian: OR za stope odgovora temeljeno na Mantel-Haenszel procjeni zajedničkog omjera izlgleda za stratificirane tablice; p-vrijednosti Cochran Mantel-Haenszelovog testa.
English: The pharmacokinetics of bortezomib were characterized following twice weekly intravenous bolus administration of 1.3 mg/m2 doses to 104 pediatric patients (2-16 years old) with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML).
Croatian: Farmakokinetika bortezomiba bila je okarakterizirana nakon primjene intravenske bolusne injekcije dva puta tjedno u dozi od 1,3 mg/m2 u 104 pedijatrijska bolesnika (u dobi od 2-16 godina) s akutnom limfoblastičnom leukemijom (ALL) ili akutnom mijeloidnom leukemijom (AML).
English: VELCADE treatment must be withheld at the onset of any ≥ Grade 3 VELCADE-related non-haematological toxicities (excluding neuropathy) or ≥ Grade 3 haematological toxicities (see also section 4.4).
Croatian: Liječenje lijekom VELCADE mora se prekinuti u slučaju nastupa bilo koje nehematološke toksičnosti ≥ stupnja 3 povezane s lijekom VELCADE (isključujući neuropatiju) ili hematološke toksičnosti ≥ stupnja 3 (također vidjeti dio 4.4).
English: VELCADE therapy should be withheld when the platelet count is < 25,000/l or, in the case of combination with melphalan and prednisone, when the platelet count is ≤ 30,000/l (see section 4.2).
Croatian: Liječenje lijekom VELCADE mora se prekinuti kad je broj trombocita < 25 000/l, a u slučaju kombinacije s melfalanom i prednizonom kad je broj trombocita ≤ 30 000/l (vidjeti dio 4.2).
English: In trials in which VELCADE was administered as induction treatment in combination with dexamethasone (study IFM-2005-01), and dexamethasone-thalidomide (study MMY-3010), the incidence of peripheral neuropathy in the combination regimens is presented in the table below:
Croatian: U ispitivanjima u kojima je VELCADE bio primijenjen kao uvodno liječenje u kombinaciji s deksametazonom (ispitivanje IFM-2005-01), i deksametazonom-talidomidom (ispitivanje MMY-3010), incidencija periferne neuropatije u kombiniranim režimima prikazana je u tablici dolje:
English: * Based on NCI Organ Dysfunction Working Group classification for categorising hepatic impairment (mild, moderate,
Croatian: Prema klasifikaciji Radne skupine za poremećaj funkcije organa Nacionalnog instituta za rak za kategorizaciju oštećenja jetre (blago, umjereno, teško).
English: Very Common Neuropathies*, Peripheral sensory neuropathy, Dysaesthesia*, Neuralgia*
Croatian: Vrlo često Neuropatije*, periferna senzorna neuropatija, disestezija*, neuralgija*
English: • Redness or pain at the injection site
Croatian: • crvenilo ili bol na mjestu primjene injekcije
English: An open label, randomised, Phase III non-inferiority study compared the efficacy and safety of the subcutaneous administration of VELCADE versus the intravenous administration.
Croatian: U otvorenom, randomiziranom ispitivanju neinferiornosti, faze III uspoređena je djelotvornost i sigurnost supkutane primjene lijeka VELCADE, u odnosu na intravensku primjenu.
English: A median of 6 cycles was received by patients in both treatment arms with 14% of subjects in the VcR-CAP group and 17% of patients in the R-CHOP group receiving 2 additional cycles.
Croatian: Medijan od 6 ciklusa primili su bolesnici u obje liječene skupine, a 14% ispitanika u VcR-CAP skupini i 17% bolesnika u R-CHOP skupini primilo je 2 dodatna ciklusa.
English: Cycles 1 to 4
Croatian: 1. do 4. Ciklus
English: • Feeling sick (nausea) or vomiting, loss of appetite
Croatian: • mučnina ili povraćanje, gubitak apetita
English: Following intravenous bolus administration of a 1.0 mg/m2 and 1.3 mg/m2 dose to 11 patients with multiple myeloma and creatinine clearance values greater than 50 ml/min, the mean first-dose maximum plasma concentrations of bortezomib were 57 and 112 ng/ml, respectively.
Croatian: Apsorpcija Nakon intravenske primjene bolus doze od 1,0 mg/m2 odnosno 1,3 mg/m2 u 11 bolesnika s multiplim mijelomom čije su vrijednosti klirensa kreatinina bile više od 50 ml/min, srednje vrijednosti maksimalne koncentracije bortezomiba u plazmi nakon prve doze iznosile su 57 odnosno 112 ng/ml.
English: • Sudden fall of blood pressure upon standing which may lead to fainting
Croatian: • nagli pad krvnog tlaka pri ustajanju, što može dovesti do nesvjestice
English: In study LYM-3002, colony stimulating factor support was given to 78% of patients in the VcR-CAP arm and 61% of patients in the R-CHOP arm.
Croatian: U ispitivanju LYM-3002, potpora u vidu faktora stimulacije kolonija primijenjena je na 78% bolesnika u VcR-CAP skupini te na 61% bolesnika u R-CHOP skupini.
English: • Hearing loss, deafness or ringing in the ears, ear discomfort
Croatian: • nagluhost, gluhoća ili zvonjenje u ušima, nelagoda u uhu
English: • Bruises, falls and injuries
Croatian: • nastanak modrica, padovi i ozljede